Mardia Samyoung Capillary Tubes Company Limited submitted statements of deviation and variation to the Bombay Stock Exchange on May 12, 2026, pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filings pertain to the quarter ended March 31, 2026, and cover eight separate preferential issue tranches executed between February 4, 2026 and February 16, 2026. In each instance, the company confirmed that no deviation or variation occurred in the utilisation of funds raised.

Overview of Preferential Issue Tranches

The company raised funds across eight tranches through preferential issues, all directed towards meeting working capital requirements. The filings were signed by Managing Director Dhaval Dharmendrabhai Joshi (DIN: 10778731) and certified by S K Bhavsar & Co., Chartered Accountants (FRN: 145880W), with the reports dated May 12, 2026, from Mumbai. No monitoring agency was appointed for any of the tranches.

The following table summarises the key details of each preferential issue tranche as reported:

Fund Utilisation and Compliance

For each of the preferential issue tranches, the original stated object was to meet working capital requirements. Across all tranches, the company reported no modification to the original object, no change in allocation, and no deviation in the amount of funds utilised as against what was originally disclosed. The fields for modified object, modified allocation, funds utilised, and deviation/variation amount were all marked as not applicable, consistent with a declaration of full compliance.

The Audit Committee comments, auditor comments, and shareholder approval fields were similarly marked as not applicable for all tranches, in line with the absence of any reported deviation or variation.

Regulatory Filing Details

The statements were filed in accordance with the following regulatory framework:

• Regulation: Regulation 32(1) of SEBI (LODR) Regulations, 2015
• Report Period: Quarter ended March 31, 2026
• Filing Date: May 12, 2026
• Mode of Fund Raising: Preferential Issue
• Monitoring Agency: Not appointed
• Certifying Auditor: S K Bhavsar & Co., Chartered Accountants, FRN: 145880W
• Signatory: Dhaval Dharmendrabhai Joshi, Managing Director, DIN: 10778731

The filings were submitted to the Listing Department of the Bombay Stock Exchange Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai 400001.

Mardia Samyoung Capillary Tubes Company Limited has completed multiple warrant conversions, resulting in the allotment of 1,17,15,000 equity shares through the conversion of fully convertible equity warrants. The company has conducted two separate warrant conversion exercises, significantly expanding its equity base and paid-up capital.

Initial Warrant Conversion - April 11, 2026

The first warrant conversion was approved by the board of directors during their meeting on April 11, 2026, involving 78,15,000 equity shares. These warrants were originally allotted on February 06, 2026, at an issue price of INR 13.50 per warrant on a preferential basis to non-promoter category investors.

Second Warrant Conversion - April 13, 2026

The board conducted another meeting on April 13, 2026, approving the conversion of an additional 39,00,000 fully convertible equity warrants. These warrants were also originally allotted to a non-promoter investor on February 06, 2026, at the same issue price of INR 13.50 per warrant.

Combined Allottee Distribution

The total equity shares from both conversions have been distributed among three non-promoter investors, demonstrating broad-based investor participation in the company's equity expansion.

Impact on Share Capital Structure

The combined warrant conversions have resulted in a substantial increase in the company's paid-up equity share capital, reflecting successful capital raising activities and providing enhanced financial resources for business operations.

Both warrant conversions were conducted in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full regulatory compliance. The successful completion of these conversions demonstrates strong investor confidence in the company's prospects and provides substantial additional equity capital for future growth initiatives.